15

3n

CLAIMS

1. A compound of Formula (I):

or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents:

a substituted or unsubstituted, (preferably aromatic), carbocyclic or heterocyclic group, said carbocyclic or heterocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein the or each ring contains 5 or 6 ring atoms, any heteroatoms being selected from N, O and S, any substituents on the Ar group being independently selected from the group consisting of:

(a) CI, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C_{1.4} lower alkyl (in particular CH₃), (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁸ are the same or different and each represents H or lower C_{1.4} alkyl, (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated lower C_{1.4} straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

CI, Br, F, OMe, NO₂ and CF₃, and (I) -OCOR¹¹, wherein R¹¹ represents a saturated or unsaturated lower C_{1.6} straight or branched hydrocarbyl group or a phenyl group;

R represents

OH, OR^{10} or $OCOR^{11}$, wherein R^{10} and R^{11} are as defined above; and R^{1} represents H or a lower C_{1-6} straight or branched hydrocarbyl group which may be

25

30

5

unsubstituted or substituted by 1, 2 or 3 substituents selected from CI, Br, F, 0Me, NO_2 and CF $_3$.

- 2. A compound according to Claim 1 wherein Ar represents a substituted or unsubstituted (preferably aromatic), heterocyclic group said heterocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein the or each ring contains 5 or 6 ring atoms, the heteroatoms being selected from N, O and S, and any substituents on the Ar group being independently selected from the group consisting of:
 - (a) CI, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₄ lower alkyl (in particular CH₃), (h) SCH₃, (i) NHCOCH₃, (j) N(R^e)(R^e) wherein R^e and R^e are the same or different and each represents H or lower C₁₄ alkyl, (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated lower C₁₄ straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

CI, Br, F, OMe, NO2 and CF3,

- and (I) -OCOR¹¹, wherein R¹¹ represents a saturated or unsaturated lower C_{1.8} straight or branched hydrocarbyl group or a phenyl group.
- 3. A compound according to any preceding claim wherein the Ar group is a substituted or unsubstituted (preferably aromatic), heterocyclic group, said heterocyclic group containing from 5 to 10 ring atoms, wherein at least one of the ring atoms is a nitrogen atom and any substituent on the ring is as defined as for Claim 1.
- A compound according to any preceding claim wherein Ar represents pyridyl or indolyl.
- A compound according to Claim 1 wherein Ar represents a substituted or unsubstituted (preferably aromatic), carbocyclic group, said carbocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein

20

25

30

the or each ring contains 5 or 6 ring atoms, and any substituents on the Ar group being independently selected from the group consisting of:

- (a) CI, (b) Br, (c) F, (d) OH, (e) NO_2 , (f) CF_3 , (g) C_{14} lower alkyl (in particular CH₃), (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁶) wherein R⁶ and R⁸ are the same or different and each represents H or lower C_{14} alkyl, (k) OR^{10} wherein R^{10} represents a saturated or unsaturated lower C_{14} straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:
 - CI, Br, F, OMe, NO2 and CF3,
- and (I) -OCOR¹¹, wherein R¹¹ represents a saturated or unsaturated lower C₁₋₈ straight or branched hydrocarbyl group or a phenyl group.
- 6. A compound according to any preceding claim wherein any substituents on the Ar group are selected from the group consisting of: NHCOCH₃, N(R⁸)(R⁸), OR¹⁰ and -OCOR¹¹, wherein R⁶, R⁸, R¹⁰ and R¹¹ are as defined in Claim 1.
- A compound according to any preceding claim wherein Ar is substituted with one
 or more OR¹⁰ groups, wherein R¹⁰ represents a saturated or unsaturated lower C_{1.0}
 straight or branched hydrocarbyl group.
- 8. A compound according to Claim 7 wherein R¹⁰ represents methyl.
- A compound according to any of Claims 5 to 8 wherein Ar is selected from phenyl or phenyl substituted with 1, 2 or 3 methoxy groups.
- 10. A compound according to any preceding claim wherein R represents an unsaturated lower C_{1-e} straight or branched hydrocarbyl group.
- A compound according to Claim 10 wherein R represents OCH=C(CH₃)₂,
 OCH₂CMe=CH₂, OCH₂CH=CH₂ or OCH₂C=CH.

- 12. A compound according to Claim 1 wherein Ar is selected from phenyl, trimethoxyphenyl, 3-pyridyl, 4-pyridyl or 3-indolyl; and R is selected from OCH=C(CH₃)₂, OCH₂CM=CH₂, OCH₂CH=CH₂ or OCH₂C=CH.
- 13. A compound according to any preceding claim wherein R^1 represents a lower C_{1-6} straight or branched hydrocarbyl group.
- 14. A compound according to Claim 13 wherein R1 represents methyl.
- 15. A compound according to Claim 5 wherein:

Ar represents

phenyl, which may be unsubstituted or substituted by one, two or three substituents independently selected from

CI, Br, F, OMe, NO₂, CF₃, C₁₋₄ lower alkyl (in particular CH₃), NMe₂, NEt₂, SCH₃ and NHCOCH₃;

thienyl, 2-furyl, 3-pyridyl, 4-pyridyl or indolyl.

R represents

OH or OCH₂R¹, wherein R¹ is selected from -CH=CMe₂, -CMe=CH₂, -CH=CH₂ and -C=CH.

- A compound according to any preceding claim wherein R⁶ and R⁸ are the same or different and each represents H or lower C₁₄ alkyl.
- 17. A compound according to any preceding claim wherein R¹⁰ and R¹¹ represents a saturated or unsaturated C_{1a} straight chain or branched hydrocarbyl group.
- 18. A compound according to any Claim 17 wherein R¹⁰ and R¹¹ are selected from methyl, ethyl, n-propyl or isopropyl.

30

5

25

20

5

- 19. A compound of Formula (I) selected from the following:
- 1-[4-methyl-7-(3-methylbut-2-enyloxy)cournarin-8-yl]-3-(pyridine-3-yl)propen-1-one (VIB 106),
- 1-[4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl]-3-phenylpropen-1-one (VIB 119),
- 1-[4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl]-3-(3,4,5-trimethoxyphenyl)-propen-1-one (VIB 120),
- 1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one VIB 122),
- 1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-phenylpropen-1-one (VIB 121),
- 1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yi]-3-(3-methoxyphenyl)propen-1-one (VIB 162),
- 1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(3,4,5-trimethoxyphenyl)propen-1-one (VIB 123),
- .1-[4-methyl-7-(allyloxy)coumarin-8-yl]-3-phenylpropen-1-one (VIB 158),
- 1-[4-methyl-7-(allyloxy)coumarin-8-yl]-3-(pyridin-3-yl)propen-1-one (VIB 161).
- 1-[4-methyl-7-(allyloxy)coumarin-8-yl]-3-(3-methoxyphenyl)propen-1-one (VIB 159).
- 1-[4-methyl-7-(allyloxy)coumarin-3-yl]-3-(3,4,5-trimethoxyphenyl)propen-1-one (VIB 160),
- 1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(3,4,5-trimethoxyp henyl)propen-1 one (VIB 126),
 - 1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-phenylpropen-1-one (VIB 124),
- 1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(pyridin-3-yl)propen-1-one (VIB 125), and
- 1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(3-methoxyphenyl)propen-1-one (VIB 163).
- 20. A compound of Formula (I) as defined in any preceding claim for use as a antiproliferative medicament.

25

- 21. Use of a compound of Formula (I) as defined in any preceding claim for the manufacture of a medicament for the treatment or prevention of neoplasms.
- Use according to Claim 21 wherein the neoplasms are located in the uterus, ovary or breast.
- 23. Use according to Claim 21 or 22 of a compound of Formula (I) for the manufacture of a medicament for the treatment of paclitaxel- and docetaxel-resistant cancer cells.
- 24. Use according to any of Claims 21 to 23 of a compound of Formula (I) in the manufacture of an antiproliferative medicament for combination therapy.
- 25. Use according to Claim 24 of a compound of Formula (I) in the manufacture of an antiproliferative medicament in combination with one or more antineoplastic agents.
- The use according to Claim 25 wherein the antineoplastic agent comprises paclitaxel or docetaxel.
- 27. The use according to Claim 19 in the manufacture of a medicament for the treatment or prevention of menopausal disorders and osteoporosis.
- 28. A pharmaceutical composition comprising one of more of the compounds of Formula (I) as defined in any preceding claim, in combination with one or more pharmaceutically acceptable excipients.
- A pharmaceutical composition according to Claim 28 further comprising one or more antineoplastic agents.

25

5

30. A pharmaceutical composition according to Claim 29 wherein the antineoplastic agent is selected from paclitaxel or docetaxel.